Capricor Therapeutics (STU:4LN2) Cyclically Adjusted FCF per Share: €-2.66 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4LN2 Capricor Therapeutics Inc STU:4LN2
35 GF Score
Price €3.32
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics Cyclically Adjusted FCF per Share?

Capricor Therapeutics STU:4LN2 +8.84% 35 Cyclically Adjusted FCF per Share is €-2.66 as of Mar. 2026. GuruFocus rates STU:4LN2 with a GF Score™ of 35/100 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Capricor Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.602. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.66 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 22.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 31.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Capricor Therapeutics was 41.90% per year. The lowest was -4.90% per year. And the median was 17.00% per year.

As of today (2026-08-01), Capricor Therapeutics's current stock price is €3.324. Capricor Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-2.66. Capricor Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Capricor Therapeutics  (STU:4LN2) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Capricor Therapeutics Cyclically Adjusted FCF per Share Related Terms


Capricor Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Cyclically Adjusted FCF per Share Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.88 -3.75 -3.22 -3.76 -2.83

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.09 -3.27 -3.02 -2.83 -2.66

STU:4LN2 vs DRTS, SPTX, SVRA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Capricor Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:4LN2
35GF Score
Capricor Therapeutics Inc STU:4LN2
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Capricor Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Capricor Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.602/330.2130*330.2130
=-0.602

Current CPI (Mar. 2026) = 330.2130.

Capricor Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -2.437 241.018 -3.339
201609 -0.937 241.428 -1.282
201612 -1.586 241.432 -2.169
201703 -2.044 243.801 -2.768
201706 -1.492 244.955 -2.011
201709 -1.150 246.819 -1.539
201712 -0.858 246.524 -1.149
201803 -1.086 249.554 -1.437
201806 -1.088 251.989 -1.426
201809 -0.876 252.439 -1.146
201812 -1.063 251.233 -1.397
201903 -0.425 254.202 -0.552
201906 -0.455 256.143 -0.587
201909 -0.400 256.759 -0.514
201912 -0.370 256.974 -0.475
202003 -0.160 258.115 -0.205
202006 -0.118 257.797 -0.151
202009 -0.128 260.280 -0.162
202012 -0.155 260.474 -0.196
202103 -0.127 264.877 -0.158
202106 -0.176 271.696 -0.214
202109 -0.140 274.310 -0.169
202112 -0.220 278.802 -0.261
202203 0.876 287.504 1.006
202206 -0.271 296.311 -0.302
202209 -0.280 296.808 -0.312
202212 -0.305 296.797 -0.339
202303 0.139 301.836 0.152
202306 -0.352 305.109 -0.381
202309 -0.342 307.789 -0.367
202312 -0.368 306.746 -0.396
202403 -0.057 312.332 -0.060
202406 -0.361 314.175 -0.379
202409 -0.319 315.301 -0.334
202412 -0.333 315.605 -0.348
202503 -0.153 319.799 -0.158
202506 -0.409 322.561 -0.419
202509 -0.442 324.800 -0.449
202512 -0.502 324.054 -0.512
202603 -0.602 330.213 -0.602

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2.66 mean?
Capricor Therapeutics (STU:4LN2) has a Cyclically Adjusted FCF per Share of €-2.66 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Cyclically Adjusted FCF per Share too high?
Capricor Therapeutics' current Cyclically Adjusted FCF per Share is €-2.66. Overall, Capricor Therapeutics has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Cyclically Adjusted FCF per Share compare to DRTS and SPTX?
Capricor Therapeutics' Cyclically Adjusted FCF per Share of €-2.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Capricor Therapeutics and its competitors. Capricor Therapeutics's current Cyclically Adjusted FCF per Share is €-2.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (STU:4LN2) is currently considered Modestly Undervalued. The current Cyclically Adjusted FCF per Share is €-2.66. Capricor Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Capricor Therapeutics (STU:4LN2), the current Cyclically Adjusted FCF per Share is €-2.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Other Exchanges CAPR:USA
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
35GF Score

Get the complete analysis for STU:4LN2

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.32
Price